Senior Vice President and Chief Medical Officer · HALOZYME THERAPEUTICS, INC. (HALO)

Dimitrios Chondros

FY2018 is the first fiscal year CompBrief holds for Dimitrios Chondros as a named executive officer of HALOZYME THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,713,894

Salary $440,750Stock awards $500,016

5th of 5 named executive officers at Halozyme Therapeutics by FY2018 total.

5 named officers on file for HALOZYME THERAPEUTICS, FY2018

Dimitrios Chondros’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • HALO’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how HALOZYME THERAPEUTICS’s whole pay program stands against its peers

  • HALOZYME THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HALO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 22, 2019 (DEF 14A).

Free

Get Dimitrios Chondros’s full pay file as a PDF — free

More than this page: up to 10 years of Dimitrios’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Dimitrios Chondros compensation by year

HALOZYME THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as HALOZYME THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$440,750
Bonus$0
Stock awards$500,016
Option awards$500,010
Non-equity incentive$263,789
Pension and deferred compensation$0
All other$9,329
Total$1,713,894

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HALOZYME THERAPEUTICS, INC. DEF 14A filed March 22, 2019, accession 0001159036-19-000013, and prior-year filings.

How this page was built: the HALOZYME THERAPEUTICS, INC. filed document, accession 0001159036-19-000013. Every figure is read from that document and cited to the page and table it appears in. Filed March 22, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU27,160$397,351—
RSU12,330$180,388—
RSU11,651$170,454—
RSU6,127$89,638—
RSU3,750$54,863—
Option16,667—$23.03
Option12,205—$8.11
Option13,467—$12.07
Option8,262—$12.24
Option47,635—$18.41

Per the Outstanding Equity Awards at Fiscal Year-End table in HALOZYME THERAPEUTICS, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

HALOZYME THERAPEUTICS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Helen TorleyPresident and Chief Executive Officer$5,799,669
Benjamin HickeyFormer Senior Vice President, Chief Commercial Officer$3,502,971
Laurie StelzerFormer Senior Vice President, Chief Financial Officer (7)$1,952,925
Harry LeonhardtFormer Senior Vice President, General Counsel$1,907,600
Dimitrios Chondros · this pageSenior Vice President and Chief Medical Officer$1,713,894

The full HALOZYME THERAPEUTICS compensation record

free company brief

This page is one person within HALOZYME THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the HALOZYME THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HALOZYME THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Dimitrios Chondros's compensation dossier · One-time report. No refunds.